Trial · NCT02424734
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Young Infants | AEs | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Term Neonates | AEs | 3 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Preterm Neonates | AEs | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Young Infants | SAEs | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Term Neonates | SAEs | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Preterm Neonates | SAEs | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Young Infants | Discontinuations Due to AEs | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Term Neonates | Discontinuations Due to AEs | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) | Ceftaroline Fosamil: Preterm Neonates | Discontinuations Due to AEs | 0 | Participants | |
| Plasma Concentration of Ceftaroline Fosamil | Ceftaroline Fosamil: All Participants | Participant 1 | 67.7 | ng/mL | |
| Plasma Concentration of Ceftaroline Fosamil | Ceftaroline Fosamil: All Participants | Participant 2 | 63.7 | ng/mL | |
| Plasma Concentration of Ceftaroline Fosamil | Ceftaroline Fosamil: All Participants | Participant 3 | 74.5 | ng/mL | |
| Plasma Concentration of Ceftaroline | Ceftaroline Fosamil: All Participants | Participant 1: 3 to 4 hrs EOI | 3420 | ng/mL | |
| Plasma Concentration of Ceftaroline | Ceftaroline Fosamil: All Participants | Participant 2: At EOI | 12400 | ng/mL | |
| Plasma Concentration of Ceftaroline | Ceftaroline Fosamil: All Participants | Participant 2: At 3 to 4 hours after EOI | 4280 | ng/mL | |
| Plasma Concentration of Ceftaroline | Ceftaroline Fosamil: All Participants | Participant 3: At EOI | 7890 | ng/mL | |
| Plasma Concentration of Ceftaroline | Ceftaroline Fosamil: All Participants | Participant 3: At 3 to 4 hours after EOI | 1760 | ng/mL | |
| Plasma Concentration of Ceftaroline | Ceftaroline Fosamil: All Participants | Participant 4: At 15 minutes to 2 hours after EOI | 9440 | ng/mL | |
| Plasma Concentration of Ceftaroline | Ceftaroline Fosamil: All Participants | Participant 4: At 5 to 7 hours after EOI | 1800 | ng/mL | |
| Plasma Concentration of Ceftaroline | Ceftaroline Fosamil: All Participants | Participant 5: At EOI | 9410 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02424734/results